MC
PBE icon

Moors & Cabot’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Moors & Cabot’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,014
Closed -$219K – 561
2014
Q2 		$219K Buy
+5,014
New +$203K 0.04% 462

Other funds holding PBE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TAM
Trillium Asset Management Boston, Massachusetts $3.01B AUM 19.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SAM
SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Moors & Cabot's PBE Position: Q3 2014 in Review

Moors & Cabot sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2014, closing a stake of 5,014 shares — an estimated $219K sold.

Moors & Cabot first reported a position in PBE in Q2 2014 and held it in 1 quarter. The position peaked at $219K in Q2 2014. 70 funds tracked by Wall St. Rank hold PBE as of Q3 2014.

  • Moors & Cabot reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2014 after selling out during the quarter.
  • Moors & Cabot sold 5,014 Invesco Biotechnology & Genome ETF shares in Q3 2014, an estimated $219K.
  • Moors & Cabot first reported a position in Invesco Biotechnology & Genome ETF in Q2 2014 and held it in 1 quarter.
  • Moors & Cabot's Invesco Biotechnology & Genome ETF position peaked at $219K in Q2 2014.
  • 70 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2014.

Based on Moors & Cabot's 13F filing for Q3 2014, filed 12 Nov 2014.